GO:0033781 cholesterol 24-hydroxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033781 cholesterol 24-hydroxylase activity is a molecular_function defined as the catalysis of cholesterol + H+ + NADPH + O2 = (24S)-24-hydroxycholesterol + H2O + NADP+.
• The enzyme responsible is CYP46A1 (cytochrome P450 46A1), a brain-enriched cytochrome P450 that initiates the major route of cholesterol elimination from the central nervous system.
• CYP46A1 activity is linked to Parkinson's disease, multiple sclerosis, brain immune homeostasis, neonatal hypoxia-ischemia, optic nerve crush injury, and neural hyperexcitation.
• Soticlestat, a selective cholesterol 24-hydroxylase inhibitor, reduces neural hyperexcitation in mice, demonstrating pharmacological tractability of this activity.
• CYP46A1 also metabolizes xenobiotics such as oral turinabol, indicating broader substrate promiscuity beyond cholesterol.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal roles of CYP46A1 in disease and to validate therapeutic hypotheses.
Description
Cholesterol 24-hydroxylase activity (GO:0033781) is a molecular_function that converts cholesterol into (24S)-24-hydroxycholesterol, the principal oxysterol mediating cholesterol turnover in the brain. This activity is catalyzed by CYP46A1, a member of the cytochrome P450 superfamily that is highly expressed in neurons and contributes to the elimination of excess cholesterol from the central nervous system. Because the blood-brain barrier prevents lipoprotein-mediated cholesterol efflux, CYP46A1-dependent 24-hydroxylation is a key pathway for maintaining brain cholesterol homeostasis. Dysregulation of this activity has been implicated in neurodegenerative and neuroinflammatory conditions, making it a target of intense research. Recent studies have expanded its relevance to Parkinson's disease, multiple sclerosis, retinal injury, and neonatal hypoxia-ischemia. Pharmacological inhibition of CYP46A1 with soticlestat has shown therapeutic potential in neural hyperexcitation, underscoring the clinical importance of this enzyme. Understanding the mechanism, regulation, and disease associations of GO:0033781 is therefore critical for researchers in neuroscience, lipid biology, and drug discovery.
cholesterol 24-hydroxylase activity At A Glance
| GO ID | GO:0033781 |
|---|---|
| GO term | cholesterol 24-hydroxylase activity |
| Ontology | molecular_function |
| Synonym | cholesterol 24-monooxygenase activity; cholesterol 24S-hydroxylase activity; cholesterol,NADPH:oxygen oxidoreductase (24-hydroxylating) activity; CYP46; CYP46A1; cytochrome P450 46A1 |
| Major function | Catalysis of cholesterol + H+ + NADPH + O2 = (24S)-24-hydroxycholesterol + H2O + NADP+ |
| Reaction type | Monooxygenation (hydroxylation) |
| Cofactors | NADPH, molecular oxygen (O2), H+ |
| Substrate | Cholesterol |
| Product | (24S)-24-hydroxycholesterol |
| Primary enzyme | CYP46A1 (cytochrome P450 46A1) |
What Is GO:0033781?
Cholesterol 24-hydroxylase activity (GO:0033781) is defined as the catalysis of the reaction: cholesterol + H+ + NADPH + O2 = (24S)-24-hydroxycholesterol + H2O + NADP+. In this monooxygenation reaction, the enzyme CYP46A1 uses molecular oxygen and NADPH to introduce a hydroxyl group at the 24S position of the cholesterol side chain, producing the oxysterol (24S)-24-hydroxycholesterol. This activity is synonymous with cholesterol 24-monooxygenase, cholesterol 24S-hydroxylase, CYP46, CYP46A1, and cytochrome P450 46A1.
Why Is cholesterol 24-hydroxylase activity Important in Cell Biology?
Cholesterol 24-hydroxylase activity is essential for brain cholesterol homeostasis because it initiates the conversion of cholesterol to 24S-hydroxycholesterol, the major oxysterol that can cross the blood-brain barrier and be further metabolized in the liver. This activity influences neuronal function, synaptic plasticity, and immune responses in the central nervous system. Dysregulation of CYP46A1 has been linked to the progression of multiple sclerosis, Parkinson's disease, and other neurological disorders. Moreover, pharmacological modulation of this activity with inhibitors such as soticlestat represents a promising therapeutic strategy for neural hyperexcitation. Thus, understanding GO:0033781 is crucial for developing treatments for neurodegenerative and neuroinflammatory diseases.
• Maintains brain cholesterol balance by converting cholesterol to 24S-hydroxycholesterol, which can be eliminated across the blood-brain barrier.
• Contributes to brain immune homeostasis at the choroid plexus.
• Promotes alpha-synuclein pathology in Parkinson's disease models.
• Linked to sterol imbalances and progression of multiple sclerosis.
• Upregulated following hypoxia-ischemia in neonatal mouse brain, suggesting a role in injury response.
• Overexpression attenuates retinal dysfunction and ganglion cell loss via Nrf2 pathway in optic nerve crush injury.
• Inhibition by soticlestat reduces neural hyperexcitation in mice, indicating therapeutic potential.
• Metabolizes xenobiotics such as oral turinabol, highlighting broader substrate specificity.
• Serves as a target for drug discovery in neurodegenerative and neuroinflammatory conditions.
• Provides a molecular marker for cholesterol turnover in the central nervous system.
What Happens During cholesterol 24-hydroxylase activity?
Substrate binding and oxygen activation
In simple terms: The enzyme grabs cholesterol and activates oxygen to modify it.
CYP46A1 binds cholesterol in its active site, where the heme iron is reduced and molecular oxygen is activated. This step requires NADPH as an electron donor, which is supplied by the redox partner cytochrome P450 oxidoreductase (POR). The activated oxygen species then attacks the cholesterol side chain at the C24 position.
Hydroxylation at C24 and product release
In simple terms: The enzyme adds a hydroxyl group to cholesterol, making 24S-hydroxycholesterol.
The activated oxygen is inserted into the C24 position of cholesterol, forming (24S)-24-hydroxycholesterol. This product is released from the active site and can subsequently cross the blood-brain barrier to be further metabolized in the liver. The reaction consumes NADPH and O2 and produces water and NADP+.
Role in brain cholesterol turnover
In simple terms: This reaction is the main way the brain gets rid of excess cholesterol.
Because the blood-brain barrier prevents direct cholesterol efflux, CYP46A1-mediated conversion to 24S-hydroxycholesterol is the primary route for cholesterol elimination from the brain. This process is critical for maintaining neuronal membrane integrity and function.
Regulation by hypoxia and injury
In simple terms: When the brain is injured or lacks oxygen, this enzyme's activity changes.
In neonatal mouse brain, cholesterol 24-hydroxylase activity is upregulated following hypoxia-ischemia, suggesting a compensatory response to injury. This upregulation may influence recovery and neuronal survival.
Key Genes Involved in GO:0033781 cholesterol 24-hydroxylase activity
The following genes and proteins are directly or indirectly involved in cholesterol 24-hydroxylase activity and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP46A1 | Primary enzyme catalyzing cholesterol 24-hydroxylation | Target for neurodegenerative disease and cholesterol metabolism studies |
| POR | Electron donor for CYP46A1 | Required for CYP46A1 catalytic activity |
| NRF2 | Transcription factor regulating antioxidant response | Mediates protective effects of CYP46A1 overexpression in retinal injury |
| SNCA | Alpha-synuclein, protein linked to Parkinson's disease | CYP46A1 promotes alpha-synuclein pathology |
| APOE | Cholesterol transport protein | Interacts with cholesterol metabolism pathways relevant to CYP46A1 |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis | Balances cholesterol levels with CYP46A1 activity |
| ABCA1 | Cholesterol efflux transporter | Contributes to cholesterol homeostasis alongside CYP46A1 |
| CYP27A1 | Sterol 27-hydroxylase | Alternative cholesterol elimination pathway |
| CYP7A1 | Cholesterol 7-alpha-hydroxylase | Liver-specific cholesterol catabolism |
| SREBP2 | Transcription factor regulating cholesterol synthesis | Coordinates cholesterol homeostasis with CYP46A1 |
| LXR | Nuclear receptor activated by oxysterols | Senses 24S-hydroxycholesterol levels |
| BDNF | Neurotrophic factor | Linked to neuronal survival affected by CYP46A1 activity |
| GFAP | Astrocyte marker | Indicates glial response in neuroinflammation models |
| IBA1 | Microglial marker | Reflects immune response modulated by CYP46A1 |
| MBP | Myelin basic protein | Marker of myelination affected in multiple sclerosis |
| NEFL | Neurofilament light chain | Biomarker of neuronal damage in neurodegeneration |
How Is cholesterol 24-hydroxylase activity Regulated?
Cholesterol 24-hydroxylase activity is regulated at multiple levels. Transcription of CYP46A1 is influenced by cholesterol availability and oxysterol feedback via LXR. Post-translational regulation includes phosphorylation and interaction with redox partners such as POR. In pathological conditions, hypoxia-ischemia upregulates CYP46A1 activity in neonatal brain. In multiple sclerosis, sterol imbalances are linked to dysregulation of cholesterol 24-hydroxylase. Pharmacological inhibition by soticlestat modulates activity in neural hyperexcitation.
cholesterol 24-hydroxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP46A1 | Parkinson's disease | Alpha-synuclein overexpression mouse model with CYP46A1 KO or overexpression |
| CYP46A1 | Multiple sclerosis | Experimental autoimmune encephalomyelitis (EAE) model |
| CYP46A1 | Neural hyperexcitation | Kainate-induced seizure model treated with soticlestat |
| CYP46A1 | Optic nerve crush injury | Mouse optic nerve crush with CYP46A1 overexpression |
| CYP46A1 | Neonatal hypoxia-ischemia | Neonatal mouse hypoxia-ischemia model |
Parkinson's disease
CYP46A1 promotes alpha-synuclein pathology in Parkinson's disease. Studies in mouse models show that cholesterol 24-hydroxylase activity exacerbates alpha-synuclein aggregation and neuronal dysfunction. This suggests that inhibiting this activity could be therapeutic.
Multiple sclerosis
Sterol imbalances and dysregulation of cholesterol 24-hydroxylase are linked to the progression of multiple sclerosis. Alterations in CYP46A1 activity contribute to demyelination and neuroinflammation.
Neural hyperexcitation
Soticlestat, a novel inhibitor of cholesterol 24-hydroxylase, shows therapeutic potential for neural hyperexcitation in mice. By reducing enzyme activity, it decreases hyperexcitability and seizures.
Retinal injury
Overexpression of CYP46A1 attenuates retinal dysfunction and ganglion cell loss via regulating the Nrf2 pathway in optic nerve crush injury. This indicates a protective role for cholesterol 24-hydroxylase activity in the retina.
From cholesterol 24-hydroxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CYP46A1 loss affect brain cholesterol metabolism? | CYP46A1 knockout mouse |
| Does a specific point mutation in CYP46A1 alter enzyme activity? | CYP46A1 point-mutation knock-in mouse |
| Can tagged CYP46A1 be used for localization studies? | CYP46A1 tagged knock-in (e.g., FLAG or GFP) |
| Does overexpression of CYP46A1 protect against retinal injury? | CYP46A1 overexpression in mouse retina |
| Does inhibition of CYP46A1 reduce seizures? | Pharmacological inhibition with soticlestat in mice |
| Does CYP46A1 modulate alpha-synuclein pathology? | CYP46A1 knockout or overexpression in alpha-synuclein models |
How to Study the cholesterol 24-hydroxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | 24S-hydroxycholesterol levels | Enzyme activity in tissues |
| RNA-seq | CYP46A1 mRNA expression | Transcriptional regulation |
| Western blot | CYP46A1 protein levels | Protein expression |
| Immunohistochemistry | CYP46A1 localization | Tissue distribution |
| CRISPR knockout | Loss of CYP46A1 function | Causal studies |
| Overexpression | Increased CYP46A1 activity | Protective effects |
| Pharmacological inhibition | Enzyme activity reduction | Therapeutic testing |
| Lipidomics | Oxysterol profile | Metabolic pathway analysis |
Enzyme activity assays
Cholesterol 24-hydroxylase activity can be measured using radiolabeled cholesterol or LC-MS/MS to quantify the production of 24S-hydroxycholesterol. These assays are used to assess enzyme kinetics and inhibitor efficacy.
Gene expression analysis
RNA-seq and qPCR are used to measure CYP46A1 mRNA levels in tissues and cell models. This helps determine transcriptional regulation in disease states.
Protein detection and localization
Western blotting and immunohistochemistry detect CYP46A1 protein and its localization in brain regions. Tagged knock-in models enable live-cell imaging.
Metabolite profiling
Lipidomics and oxysterol profiling by mass spectrometry quantify 24S-hydroxycholesterol and other sterols in biological samples, providing a readout of pathway activity.
How CRISPR Can Be Used to Study GO:0033781 cholesterol 24-hydroxylase activity
Knockout
CRISPR knockout of CYP46A1 eliminates cholesterol 24-hydroxylase activity, enabling studies of its role in brain cholesterol homeostasis and disease. Knockout mice show altered cholesterol metabolism and are used to test hypotheses about CYP46A1 in Parkinson's disease and multiple sclerosis.
Point Mutation
Point mutations can be introduced into the CYP46A1 gene to mimic human variants or to abolish catalytic activity. These models help dissect the contribution of enzymatic activity versus other functions of the protein.
Knock-in
Knock-in of tagged CYP46A1 (e.g., FLAG, GFP) allows visualization and pull-down of the enzyme in vivo. This is useful for studying protein interactions and localization.
Overexpression
Overexpression of CYP46A1 via transgenic or viral vectors increases cholesterol 24-hydroxylase activity. This approach has shown protective effects in retinal injury and is used to test therapeutic potential.
How EDITGENE Supports cholesterol 24-hydroxylase activity Research
Researchers studying cholesterol 24-hydroxylase activity-related genes often need to determine whether a candidate gene is causally involved in disease or metabolism. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for cholesterol 24-hydroxylase activity research.
Frequently Asked Questions About cholesterol 24-hydroxylase activity
What is cholesterol 24-hydroxylase activity?
Cholesterol 24-hydroxylase activity (GO:0033781) is the enzymatic conversion of cholesterol to (24S)-24-hydroxycholesterol, catalyzed primarily by CYP46A1.
What gene encodes cholesterol 24-hydroxylase?
The CYP46A1 gene encodes the enzyme cytochrome P450 46A1, which carries out cholesterol 24-hydroxylase activity.
What diseases are associated with cholesterol 24-hydroxylase?
It is linked to Parkinson's disease, multiple sclerosis, neural hyperexcitation, and retinal injury.
How is cholesterol 24-hydroxylase activity measured?
It is typically measured by LC-MS/MS quantification of 24S-hydroxycholesterol or by using radiolabeled cholesterol assays.
What is the role of CYP46A1 in the brain?
CYP46A1 converts cholesterol to 24S-hydroxycholesterol, which can cross the blood-brain barrier, thus maintaining brain cholesterol homeostasis.
Can cholesterol 24-hydroxylase be inhibited therapeutically?
Yes, soticlestat is a novel inhibitor that shows therapeutic potential for neural hyperexcitation in mice.
What are the substrates of cholesterol 24-hydroxylase?
The primary substrate is cholesterol, but CYP46A1 can also metabolize xenobiotics such as oral turinabol.
How does cholesterol 24-hydroxylase affect alpha-synuclein?
CYP46A1 promotes alpha-synuclein pathology in Parkinson's disease models.
Is cholesterol 24-hydroxylase involved in multiple sclerosis?
Yes, sterol imbalances and dysregulation of this enzyme are linked to multiple sclerosis progression.
What model systems are used to study cholesterol 24-hydroxylase?
Knockout mice, overexpression models, and pharmacological inhibition with soticlestat are commonly used.
Conclusion
Cholesterol 24-hydroxylase activity (GO:0033781) is a critical molecular function for brain cholesterol turnover and is implicated in a range of neurological disorders. The enzyme CYP46A1 catalyzes the formation of 24S-hydroxycholesterol, influencing neuronal health, immune homeostasis, and disease progression. Pharmacological and genetic tools, including CRISPR models, are essential for advancing our understanding and developing targeted therapies. EDITGENE provides comprehensive services to support this research.
References
- 1. Dai L et al.. 2025. The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.. PLoS Biol 23(2):e3002974 PMID: 39964974
- 2. Griffiths L et al.. 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis.. Brain Pathol 35(5):e70001 PMID: 40045480
- 3. Tsitsou-Kampeli A et al.. 2023. Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis.. Cell Rep Med 4(11):101278 PMID: 37944529
- 4. Lu F et al.. 2018. Upregulation of cholesterol 24-hydroxylase following hypoxia-ischemia in neonatal mouse brain.. Pediatr Res 83(6):1218-1227 PMID: 29718007
- 5. Long Z et al.. 2025. Overexpression of cholesterol 24-hydroxylase CYP46A1 attenuates retinal dysfunction and ganglion cell loss via regulating the Nrf2 pathway in optic nerve crush injury.. Exp Eye Res 261:110649 PMID: 40975483
- 6. Nishi T et al.. 2020. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice.. Sci Rep 10(1):17081 PMID: 33051477
- 7. Pikuleva IA. 2006. Cholesterol-metabolizing cytochromes P450.. Drug Metab Dispos 34(4):513-20 PMID: 16434543
- 8. Putkaradze N et al.. 2021. Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1.. J Steroid Biochem Mol Biol 212:105927 PMID: 34089835
